Comparing Adrenaline and Dopamine to Treat Fluid Refractory Septic Shock in Children Aged 1 Month to 12 Years

What this Trial Is About

Researchers are evaluating the effectiveness of two drugs, adrenaline and dopamine, for treating fluid refractory septic shock in children. This serious condition requires urgent treatment, and the study aims to compare how well these drugs work by measuring heart rate, Glasgow Coma Scale GCS, capillary refill time, peripheral pulse, urine output, and systolic blood pressure. This randomized control trial focuses on children diagnosed with this type of septic shock to determine which drug better corrects these vital parameters over time. Participants will be randomly assigned to receive either adrenaline at a dose of 0.1-0.3 micrograms per kilogram per minute or dopamine at a dose of 10-20 micrograms per kilogram per minute once diagnosed with fluid refractory septic shock. These drugs will be administered continuously during the trial period, and the treatment groups include Group A adrenaline and Group B dopamine. The study does not involve any masking or blinding, and treatments are given based on random assignment. During the study, researchers will monitor participants closely for changes in blood pressure, pulse, capillary refill time, urine output, and GCS over a 6-hour period. Additional assessments include the Sequential Organ Failure Assessment SOFA score at 6 hours to evaluate organ function. The trial will enroll children aged 1 month to 12 years, and their vital signs and clinical status will be tracked to compare the effects of the two drugs. The participation duration covers the critical early hours of treatment when fluid refractory septic shock is addressed.

Adrenaline V/s Dopamine in Fuid Refractory Septic Shock